ADMA Biologics, Inc. Company Review & Valuation
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.
Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
The company also operates source plasma collection facilities in Norcross and Marietta, Georgia.
In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency.
It distributes its products through independent distributors, sales agents, specialty pharmacies, and others.
The ADMA Biologics, Inc.
was founded in 2004 and is headquartered in Ramsey, New Jersey.